Business
RepliCel CEO Provides Company Outlook
RepliCel CEO Provides Company Outlook.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel CEO Provides Company Outlook\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nRepliCel CEO Provides Company Outlook\nPR Newswire\nVANCOUVER, May 25, 2017\n\n\n\nA data-rich 2017 positions RepliCel for maturity through the next phase of its product development, research programs, and revenue generation\n\n\n\nVANCOUVER, May 25, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (\"RepliCel\" or the \"Company\"), a regenerative medicine company addressing large-market opportunities with innovative technologies in aesthetics and sports injury/orthopedics, today unveiled its go-forward strategy.\n\nIn the first few months of 2017, the Company made pivotal announcements based on data collected from all three of its cell therapy programs. Furthermore, RepliCel continues to make significant progress on its nearest-term commercial asset, the dermal injector (RCI-02). \n\nBuilding on a decade of the Company's discovery, pre-clinical work, and successful first-in-human clinical data, RepliCel has formulated a strategic plan for 2017 through 2019 focused on maturing its assets through three distinct pillars:\n\n\ncommercializing the Company's dermal injector;\nresearch and development to enhance clinical efficacy, optimize manufacturing, and strengthen the Company's intellectual property portfolio; and\npreparing and launching phase II clinical trials.\n\nThe plan includes several key milestones anticipated to be part of the Company's next 30 months including:\n\n\nbuilding and testing the commercial-grade prototypes of RepliCel's next-generation dermal injector;\npreparing the RCI-02 device for marketing approval in Europe (CE-mark);\nexecuting an application-focused commercialization agreement for RCI-02 with a multi-national partner, including the payment of non-dilutive licensing/milestone fees and ongoing sales royalties;\nlaunching and executing a molecular marker study anticipated to add significant value to the Company's intellectual property, manufacturing technologies, and the enhancem...